PORTAGE BIOTECH INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.236 USD | -1.67% |
|
-38.51% | -84.63% |
| Apr. 15 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
| Apr. 12 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.75M |
|---|---|---|---|---|---|
| Net income 2024 * | -51M | Net income 2025 * | -16M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.09
x | P/E ratio 2025 * |
-0.37
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.18% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +8.50% | ||
| 1 week | -52.00% | ||
| Current month | -57.39% | ||
| 1 month | -58.26% | ||
| 3 months | -74.47% | ||
| 6 months | -89.79% | ||
| Current year | -86.81% |
1 week
0.20
0.46
1 month
0.200.80
Current year
0.202.04
1 year
0.204.40
3 years
0.2044.98
5 years
0.0144.98
10 years
0.0165.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Walters
CEO | Chief Executive Officer | 57 | 16-07-31 |
Allan Shaw
DFI | Director of Finance/CFO | 59 | 20-05-11 |
Steve Innaimo
COO | Chief Operating Officer | - | 19-01-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregory Bailey
FOU | Founder | 68 | 72-12-31 |
Steven Mintz
BRD | Director/Board Member | 57 | 16-04-05 |
Robert Glassman
BRD | Director/Board Member | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.2798 | +16.58% | 219 000 |
| 24-04-18 | 0.24 | +8.50% | 146,692 |
| 24-04-17 | 0.2212 | -21.28% | 271,444 |
| 24-04-16 | 0.281 | -17.35% | 275,996 |
| 24-04-15 | 0.34 | -25.27% | 630,863 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotes
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Companyâs access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Companyâs portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Companyâs portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.
Calendar
2024-07-28
- Q4 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.24
USD
Average target price
7
USD
Spread / Average Target
+2,816.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -86.81% | 4.75M | |
| -1.82% | 41.35B | |
| +42.21% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- PRTG Stock
